In this study, the conversion of maintenance immunosuppression from calcineurin inhibitors to mTOR inhibitors for clinical indications did appear to reduce the incidence of NMSC in kidney and liver transplant recipients.
Authors: Susan L. Murray, Fergus E. Daly, Patrick O’Kelly, Eamonn O’Leary, Sandra Deady, James P. O’Neill, Alexander Dudley, Nicholas R. Rutledge, Aiden McCormick, Diarmuid D. Houlihan, Yvonne Williams, Patrick G. Morris, Siona Ni Raghallaigh, Fergal J. Moloney, Donal J. Sexton & Peter J. Conlon
Date: RENAL FAILURE ,2020, VOL. 42, NO. 1, 607–612
Cancer-attributable mortality is higher in kidney transplant recipients with non-melanoma skin cancer compared with non-transplant patients. The American Joint Committee on Cancer staging should reflect the increased hazard of death in these immunosuppressed patients.
Authors: Susan L. Murray , Eamonn O’Leary, A´ ine M. De Bhailı´s, Sandra Deady, Fergus E. Daly, Patrick O’Kelly, Yvonne Williams, James P. O’Neill, Donal J. Sexton and Peter J. Conlon.
Date: Nephrol Dial Transplant (2020) 1–9
A molecular diagnosis is possible using genomic testing in around 4% of 37 clinically unscreened patients undergoing renal biopsy. Genetic screening may be useful for 38 diagnosis in a subset of CKD patients, but is most valuable when applied to patients with 39 suspected heritable forms of kidney disease. 40 Downloaded from molecularcasestudies.cshlp.org on August 9, 2020 - Published by Cold Spring Harbor Laboratory Press
Authors: Katherine A. Benson, Susan L. Murray, Ross Doyled, Brendan Doylee, Anthony M. Dormane, Denise Sadlier, Eoin Brennan, Margaret Large, Gianpiero L. Cavalleria, Catherine Godson, Peter J. Conlon.
Date: molecularcasestudies.cshlp.org on August 9, 2020
We present updates in genomic medicine for renal disease, how genetic testing integrates with our knowledge of renal histopathology and how the two modalities may interact to enhance patient care.
Authors: Susan L. Murray Neil K Fennelly, Brendan Doyle, Sally Ann Lynch and Peter J. Conlon.
Date: Nephrol Dial Transplant (2020) 35: 1113–1132
Coronavirus disease 2019 (COVID-19) continues to affect millions of people around the globe. As data emerge, it is becoming more evident that extrapulmonary organ involvement, particularly the kidneys, highly influence mortality. The incidence of acute kidney injury has been estimated to be 30% in COVID-19 non-survivors. Current evidence suggests four broad mechanisms of renal injury: Hypovolaemia, acute respiratory distress syndrome related, cytokine storm and direct viral invasion as seen on renal autopsy findings. We look to critically assess the epidemiology, pathophysiology and management of kidney injury in COVID-19.
Authors: Ahmed AR, Ebad CA, Stoneman S, Satti MM, Conlon PJ
Date:World J Nephrol 2020 November 29; 9(2): 9-42
Autosomal dominant tubulo-interstitial kidney disease due to UMOD mutations (ADTKDUMOD)
is a rare condition associated with high variability in the age of end-stage kidney disease (ESKD).
The minor allele of rs4293393, located in the promoter of the UMOD gene, is present in 19% of the population and downregulates uromodulin production by approximately 50% and might affect the age of
ESKD. The goal of this study was to better understand the genetic and clinical characteristics of ADTKDUMOD and to perform a Mendelian randomization study to determine if the minor allele of rs4293393 was associated with better kidney survival.
Authors: Kendrah Kidd1, Petr Vylet’al, Céline Schaeffer, Eric Olinger, Martina Zivná, Katerina Hodanová, Victoria Robins, Emily Johnson, Abbigail Taylor, Lauren Martin, Claudia Izzi, Sofia C. Jorge, Joaquim Calado, Rosa J. Torres, Karl Lhotta, Dominik Steubl1, Daniel P. Gale, Christine Gast, Eva Gombos, Hannah C. Ainsworth, Ying Maggie Chen, Jorge Reis Almeida, Cintia Fernandes de Souza, Catarina Silveira, Rita Raposeiro, Nelson Weller, Peter J. Conlon, Susan L. Murray, Katherine A. Benson,
Gianpiero L. Cavalleri, Miroslav Votruba, Alena Vrbacká, Antonio Amoroso, Daniela Gianchino, Gianluca Caridi, GianMarco Ghiggeri, Jasmin Divers, Francesco Scolari, Olivier Devuyst, Luca Rampoldi, Stanislav Kmoch and Anthony J. Bleyer
Date: Kidney International Reports (2020) 5, 1472–1485
The survival of incident dialysis patients’ end-stage kidney disease in some European and American has been reported to improve in modern era compared to earlier periods. However, in Ireland, this has not been well documented. Aim To investigate the survival outcomes of incident end-stage kidney failure dialysis patients in a tertiary center over a 24-year period, 1993–2017.
Authors: Elhussein A. E. Elhassan , Sinead Stoneman, Patrick O’Kelly, Veronica Francis, Mark Denton, Colm Magee, Declan G. de Freitas, Conall M. O’Seaghdha, John Donohoe, Peter J. Conlon
Date: Irish Journal of Medical Science (1971 -), 2020 , https://doi.org/10.1007/s11845-020-02481-3
The standard low-phosphorus diet restricts pulses, nuts, and whole grains and other high phosphorus foods to control hyperphosphatemia. We conducted a randomized controlled trial to evaluate the effectiveness, safety, and tolerability of the modified diet, which introduced some pulses and nuts, increased the use of whole grains, increased focus on the avoidance of phosphate additives, and introduced the prescription of low-biological-value protein such as bread.
Authors: Fiona N. Byrne, Barbara A. Gillman, Mairead Kiely, Brendan Palmer, Frances Shiely, Patricia M. Kearney, Joyce Earlie, Maria B. Bowles, Fiona M. Keohane, Pauline P. Connolly, Sarah Wade, Theresa A. Rennick, Bernice L. Moore, Oonagh N. Smith, Celene M. Sands, Orla Slevin, Denise C. McCarthy, Karina M. Brennan, Halóg Mellett, Darren Dahly, Eoin Bergin, Liam F. Casserly, Peter J. Conlon, Kieran Hannan, John Holian, David W. Lappin, Yvonne M. O’Meara, George J. Mellotte, Donal Reddan, Alan Watson and Joseph Eustace.
Date: Kidney Int Rep (2020) 5, 1945–1955; https://doi.org/10.1016/j.ekir.2020.08.008
In patients with ESRD due to ADTKD, we demonstrate that transplant outcomes are comparable with the general transplant population. There is no evidence that ADTKD can recur after transplantation.
Authors: Sarah Cormican, Claire Kennedy, Dervla M Connaughton, Patrick O'Kelly, Susan Murray, Martina Živná, Stanislav Kmoch, Neil K Fennelly, Katherine A Benson , Eoin T Conlon, Gianpiero L Cavalleri, Claire Foley, Brendan Doyle, Anthony Dorman, Mark A Little, Peter Lavin, Kendrah Kidd, Anthony J Bleyer, Peter J Conlon
Date: Clinical Transplantation.2020 Feb;34(2):e13783